AEBODSYS,AETERM,col1,param,value,col2,AETERM_ORD,AEBODSYS_ORD
Any Body System,Any Body System,Placebo,distinct_n,69,n_pct,1,1
Any Body System,Any Body System,Placebo,distinct_pct,1,n_pct,1,1
Any Body System,Any Body System,Placebo,n,301,n_aes,1,1
Any Body System,Any Body System,Xanomeline High Dose,distinct_n,70,n_pct,1,1
Any Body System,Any Body System,Xanomeline High Dose,distinct_pct,1,n_pct,1,1
Any Body System,Any Body System,Xanomeline High Dose,n,436,n_aes,1,1
Any Body System,Any Body System,Xanomeline Low Dose,distinct_n,86,n_pct,1,1
Any Body System,Any Body System,Xanomeline Low Dose,distinct_pct,1,n_pct,1,1
Any Body System,Any Body System,Xanomeline Low Dose,n,454,n_aes,1,1
CARDIAC DISORDERS,CARDIAC DISORDERS,Placebo,distinct_n,13,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Placebo,distinct_pct,0.18840579710144928,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Placebo,n,27,n_aes,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,15,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.21428571428571427,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline High Dose,n,30,n_aes,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,16,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.18604651162790695,n_pct,2,10
CARDIAC DISORDERS,CARDIAC DISORDERS,Xanomeline Low Dose,n,34,n_aes,2,10
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Placebo,n,1,n_aes,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline High Dose,n,3,n_aes,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,2,1
ATRIAL FIBRILLATION,CARDIAC DISORDERS,Xanomeline Low Dose,n,3,n_aes,2,1
ATRIAL FLUTTER,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline High Dose,n,2,n_aes,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,2
ATRIAL FLUTTER,CARDIAC DISORDERS,Xanomeline Low Dose,n,1,n_aes,2,2
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,3
ATRIAL HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,3
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Placebo,n,1,n_aes,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,4
ATRIOVENTRICULAR BLOCK FIRST DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,n,1,n_aes,2,4
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Placebo,distinct_n,2,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline High Dose,n,2,n_aes,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,2,5
ATRIOVENTRICULAR BLOCK SECOND DEGREE,CARDIAC DISORDERS,Xanomeline Low Dose,n,2,n_aes,2,5
BRADYCARDIA,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Placebo,n,4,n_aes,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,6
BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,6
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Placebo,n,1,n_aes,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,7
BUNDLE BRANCH BLOCK LEFT,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,7
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,8
BUNDLE BRANCH BLOCK RIGHT,CARDIAC DISORDERS,Xanomeline Low Dose,n,1,n_aes,2,8
CARDIAC DISORDER,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline High Dose,n,1,n_aes,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,9
CARDIAC DISORDER,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,9
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Placebo,n,1,n_aes,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,11
CARDIAC FAILURE CONGESTIVE,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,11
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Placebo,distinct_n,4,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Placebo,distinct_pct,0.05797101449275362,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Placebo,n,4,n_aes,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,4,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.05714285714285714,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline High Dose,n,8,n_aes,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,2,12
MYOCARDIAL INFARCTION,CARDIAC DISORDERS,Xanomeline Low Dose,n,4,n_aes,2,12
PALPITATIONS,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,2,13
PALPITATIONS,CARDIAC DISORDERS,Xanomeline Low Dose,n,2,n_aes,2,13
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,14
SINUS ARRHYTHMIA,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,14
SINUS BRADYCARDIA,CARDIAC DISORDERS,Placebo,distinct_n,2,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,8,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.11428571428571428,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,n,12,n_aes,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,7,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.08139534883720931,n_pct,2,15
SINUS BRADYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,n,10,n_aes,2,15
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,n,1,n_aes,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,16
SUPRAVENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,n,2,n_aes,2,16
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,17
SUPRAVENTRICULAR TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,n,2,n_aes,2,17
TACHYCARDIA,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Placebo,n,2,n_aes,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,18
TACHYCARDIA,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,18
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline High Dose,n,1,n_aes,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,2,19
VENTRICULAR EXTRASYSTOLES,CARDIAC DISORDERS,Xanomeline Low Dose,n,4,n_aes,2,19
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Placebo,distinct_n,1,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Placebo,n,1,n_aes,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,2,20
VENTRICULAR HYPERTROPHY,CARDIAC DISORDERS,Xanomeline Low Dose,n,0,n_aes,2,20
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Placebo,distinct_n,0,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Placebo,distinct_pct,0,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Placebo,n,0,n_aes,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline High Dose,n,0,n_aes,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,2,21
WOLFF-PARKINSON-WHITE SYNDROME,CARDIAC DISORDERS,Xanomeline Low Dose,n,2,n_aes,2,21
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,distinct_n,0,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,distinct_pct,0,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,n,0,n_aes,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,distinct_n,2,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,n,2,n_aes,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,3,1
"CONGENITAL, FAMILIAL AND GENETIC DISORDERS","CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,n,1,n_aes,3,1
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,distinct_n,0,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,distinct_pct,0,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Placebo,n,0,n_aes,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,distinct_n,2,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline High Dose,n,2,n_aes,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,3,2
VENTRICULAR SEPTAL DEFECT,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",Xanomeline Low Dose,n,1,n_aes,3,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Placebo,distinct_n,1,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Placebo,n,2,n_aes,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,n,1,n_aes,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,4,2
EAR AND LABYRINTH DISORDERS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,n,3,n_aes,4,2
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Placebo,distinct_n,0,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Placebo,distinct_pct,0,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Placebo,n,0,n_aes,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,n,0,n_aes,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,4,1
CERUMEN IMPACTION,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,n,1,n_aes,4,1
EAR PAIN,EAR AND LABYRINTH DISORDERS,Placebo,distinct_n,1,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Placebo,n,2,n_aes,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,n,0,n_aes,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,4,3
EAR PAIN,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,n,0,n_aes,4,3
TINNITUS,EAR AND LABYRINTH DISORDERS,Placebo,distinct_n,0,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Placebo,distinct_pct,0,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Placebo,n,0,n_aes,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,n,0,n_aes,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,4,4
TINNITUS,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,n,1,n_aes,4,4
VERTIGO,EAR AND LABYRINTH DISORDERS,Placebo,distinct_n,0,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Placebo,distinct_pct,0,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Placebo,n,0,n_aes,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline High Dose,n,1,n_aes,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,4,5
VERTIGO,EAR AND LABYRINTH DISORDERS,Xanomeline Low Dose,n,1,n_aes,4,5
EYE DISORDERS,EYE DISORDERS,Placebo,distinct_n,4,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Placebo,distinct_pct,0.05797101449275362,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Placebo,n,8,n_aes,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline High Dose,n,2,n_aes,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,5,4
EYE DISORDERS,EYE DISORDERS,Xanomeline Low Dose,n,2,n_aes,5,4
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Placebo,distinct_n,0,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Placebo,distinct_pct,0,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Placebo,n,0,n_aes,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,5,1
CONJUNCTIVAL HAEMORRHAGE,EYE DISORDERS,Xanomeline Low Dose,n,1,n_aes,5,1
CONJUNCTIVITIS,EYE DISORDERS,Placebo,distinct_n,2,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Placebo,n,4,n_aes,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,5,2
CONJUNCTIVITIS,EYE DISORDERS,Xanomeline Low Dose,n,0,n_aes,5,2
EYE ALLERGY,EYE DISORDERS,Placebo,distinct_n,1,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Placebo,n,1,n_aes,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,5,3
EYE ALLERGY,EYE DISORDERS,Xanomeline Low Dose,n,0,n_aes,5,3
EYE PRURITUS,EYE DISORDERS,Placebo,distinct_n,1,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Placebo,n,1,n_aes,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,5,5
EYE PRURITUS,EYE DISORDERS,Xanomeline Low Dose,n,0,n_aes,5,5
EYE SWELLING,EYE DISORDERS,Placebo,distinct_n,1,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Placebo,n,1,n_aes,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,5,6
EYE SWELLING,EYE DISORDERS,Xanomeline Low Dose,n,0,n_aes,5,6
GLAUCOMA,EYE DISORDERS,Placebo,distinct_n,1,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Placebo,n,1,n_aes,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline High Dose,n,0,n_aes,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,5,7
GLAUCOMA,EYE DISORDERS,Xanomeline Low Dose,n,0,n_aes,5,7
VISION BLURRED,EYE DISORDERS,Placebo,distinct_n,0,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Placebo,distinct_pct,0,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Placebo,n,0,n_aes,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline High Dose,n,2,n_aes,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,5,8
VISION BLURRED,EYE DISORDERS,Xanomeline Low Dose,n,1,n_aes,5,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,17,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.2463768115942029,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Placebo,n,26,n_aes,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,20,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.2857142857142857,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,35,n_aes,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,16,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.18604651162790695,n_pct,6,8
GASTROINTESTINAL DISORDERS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,26,n_aes,6,8
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,1,n_aes,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,1
ABDOMINAL DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,1
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Placebo,n,1,n_aes,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,2,n_aes,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,6,2
ABDOMINAL PAIN,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,3,n_aes,6,2
CONSTIPATION,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Placebo,n,1,n_aes,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,3
CONSTIPATION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,3
DIARRHOEA,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,9,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.13043478260869565,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Placebo,n,10,n_aes,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,3,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,3,n_aes,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,6,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.06976744186046512,n_pct,6,4
DIARRHOEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,8,n_aes,6,4
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Placebo,n,2,n_aes,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,1,n_aes,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,6,5
DYSPEPSIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,2,n_aes,6,5
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,6,6
DYSPHAGIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,1,n_aes,6,6
FLATULENCE,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Placebo,n,2,n_aes,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,7
FLATULENCE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,7
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,1,n_aes,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,9
GASTROINTESTINAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,9
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Placebo,n,1,n_aes,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,10
GASTROOESOPHAGEAL REFLUX DISEASE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,10
GLOSSITIS,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Placebo,n,1,n_aes,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,11
GLOSSITIS,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,11
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,1,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Placebo,n,2,n_aes,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,12
HIATUS HERNIA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,12
NAUSEA,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,3,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.04347826086956521,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Placebo,n,3,n_aes,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,6,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.08571428571428572,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,13,n_aes,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,6,13
NAUSEA,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,5,n_aes,6,13
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,0,n_aes,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,6,14
RECTAL HAEMORRHAGE,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,2,n_aes,6,14
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,4,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.05714285714285714,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,5,n_aes,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,15
SALIVARY HYPERSECRETION,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,15
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,0,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Placebo,n,0,n_aes,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,1,n_aes,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,6,16
STOMACH DISCOMFORT,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,0,n_aes,6,16
VOMITING,GASTROINTESTINAL DISORDERS,Placebo,distinct_n,3,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Placebo,distinct_pct,0.04347826086956521,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Placebo,n,3,n_aes,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_n,6,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,distinct_pct,0.08571428571428572,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline High Dose,n,8,n_aes,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_n,4,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,distinct_pct,0.04651162790697674,n_pct,6,17
VOMITING,GASTROINTESTINAL DISORDERS,Xanomeline Low Dose,n,5,n_aes,6,17
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,21,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.30434782608695654,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,48,n_aes,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,36,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.5142857142857142,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,118,n_aes,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,51,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.5930232558139535,n_pct,7,25
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,126,n_aes,7,25
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,1
APPLICATION SITE BLEEDING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,1
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,5,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.07246376811594203,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,9,n_aes,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,7,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.1,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,12,n_aes,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,9,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.10465116279069768,n_pct,7,2
APPLICATION SITE DERMATITIS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,15,n_aes,7,2
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,3
APPLICATION SITE DESQUAMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,3
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,4
APPLICATION SITE DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,4
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,5
APPLICATION SITE DISCOLOURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,5
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,3,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.04347826086956521,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,3,n_aes,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,14,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.2,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,22,n_aes,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,13,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.1511627906976744,n_pct,7,6
APPLICATION SITE ERYTHEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,21,n_aes,7,6
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,1,n_aes,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,7
APPLICATION SITE INDURATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,7
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,3,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.04347826086956521,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,7,n_aes,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,9,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.12857142857142856,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,16,n_aes,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,9,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.10465116279069768,n_pct,7,8
APPLICATION SITE IRRITATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,18,n_aes,7,8
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,2,n_aes,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,9
APPLICATION SITE PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,9
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,3,n_aes,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,10
APPLICATION SITE PERSPIRATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,10
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,6,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.08695652173913043,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,10,n_aes,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,21,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.3,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,34,n_aes,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,23,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.26744186046511625,n_pct,7,11
APPLICATION SITE PRURITUS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,34,n_aes,7,11
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,2,n_aes,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,12
APPLICATION SITE REACTION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,12
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,3,n_aes,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,13
APPLICATION SITE SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,13
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,2,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,7,14
APPLICATION SITE URTICARIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,14
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,2,n_aes,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,5,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,5,n_aes,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,5,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.05813953488372093,n_pct,7,15
APPLICATION SITE VESICLES,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,6,n_aes,7,15
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,16
APPLICATION SITE WARMTH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,16
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,2,n_aes,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,17
ASTHENIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,17
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,18
CHEST DISCOMFORT,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,18
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,2,n_aes,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,19
CHEST PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,19
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,3,n_aes,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,20
CHILLS,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,20
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,21
CYST,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,21
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,1,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,2,n_aes,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,5,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,5,n_aes,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,5,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.05813953488372093,n_pct,7,22
FATIGUE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,5,n_aes,7,22
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,23
FEELING ABNORMAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,23
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,0,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,7,24
FEELING COLD,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,0,n_aes,7,24
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,26
INFLAMMATION,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,26
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,3,n_aes,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,27
MALAISE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,27
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,2,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,7,28
OEDEMA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,28
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,2,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,5,n_aes,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,2,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,3,n_aes,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,29
OEDEMA PERIPHERAL,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,29
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,1,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,1,n_aes,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,30
PAIN,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,30
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,2,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,2,n_aes,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,31
PYREXIA,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,31
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,32
SECRETION DISCHARGE,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,2,n_aes,7,32
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,33
SUDDEN DEATH,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,33
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,34
SWELLING,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,34
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_n,0,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,distinct_pct,0,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Placebo,n,0,n_aes,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_n,0,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,distinct_pct,0,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline High Dose,n,0,n_aes,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_n,1,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,7,35
ULCER,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,Xanomeline Low Dose,n,1,n_aes,7,35
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Placebo,distinct_n,1,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Placebo,n,1,n_aes,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline High Dose,n,0,n_aes,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,8,1
HEPATOBILIARY DISORDERS,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,n,0,n_aes,8,1
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Placebo,distinct_n,1,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Placebo,n,1,n_aes,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline High Dose,n,0,n_aes,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,8,2
HYPERBILIRUBINAEMIA,HEPATOBILIARY DISORDERS,Xanomeline Low Dose,n,0,n_aes,8,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Placebo,n,0,n_aes,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,9,2
IMMUNE SYSTEM DISORDERS,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,n,2,n_aes,9,2
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Placebo,n,0,n_aes,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,9,1
HYPERSENSITIVITY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,n,2,n_aes,9,1
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Placebo,n,0,n_aes,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,9,3
SEASONAL ALLERGY,IMMUNE SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,9,3
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,16,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.2318840579710145,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Placebo,n,35,n_aes,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,13,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.18571428571428572,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,20,n_aes,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,10,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.11627906976744186,n_pct,10,8
INFECTIONS AND INFESTATIONS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,18,n_aes,10,8
BRONCHITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Placebo,n,1,n_aes,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,1
BRONCHITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,1
CELLULITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,2
CELLULITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,1,n_aes,10,2
CERVICITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Placebo,n,2,n_aes,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,3
CERVICITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,3
CYSTITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Placebo,n,1,n_aes,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,1,n_aes,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,4
CYSTITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,4
EAR INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,2,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,4,n_aes,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,5
EAR INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,5
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Placebo,n,1,n_aes,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,6
GASTROENTERITIS VIRAL,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,6
HORDEOLUM,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,1,n_aes,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,7
HORDEOLUM,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,7
INFLUENZA,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Placebo,n,2,n_aes,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,1,n_aes,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,9
INFLUENZA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,1,n_aes,10,9
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,2,n_aes,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,10
LOCALISED INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,1,n_aes,10,10
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,2,n_aes,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,11
LOWER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,11
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,2,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Placebo,n,4,n_aes,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,6,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.08571428571428572,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,8,n_aes,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,4,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.04651162790697674,n_pct,10,12
NASOPHARYNGITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,9,n_aes,10,12
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,13
ONYCHOMYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,1,n_aes,10,13
PNEUMONIA,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,14
PNEUMONIA,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,2,n_aes,10,14
RHINITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,1,n_aes,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,15
RHINITIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,15
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,6,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.08695652173913043,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,12,n_aes,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,3,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,5,n_aes,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,16
UPPER RESPIRATORY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,2,n_aes,10,16
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,2,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,4,n_aes,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,1,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,1,n_aes,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,17
URINARY TRACT INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,17
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,1,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Placebo,n,2,n_aes,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,10,18
VAGINAL MYCOSIS,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,0,n_aes,10,18
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_n,0,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Placebo,distinct_pct,0,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Placebo,n,0,n_aes,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_n,0,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline High Dose,n,0,n_aes,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,10,19
VIRAL INFECTION,INFECTIONS AND INFESTATIONS,Xanomeline Low Dose,n,1,n_aes,10,19
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,4,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.05797101449275362,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,9,n_aes,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,5,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,8,n_aes,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,5,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.05813953488372093,n_pct,11,6
"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,12,n_aes,11,6
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,1,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.0144927536231884,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,1,n_aes,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,2,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,3,n_aes,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,1,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,11,1
CONTUSION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,3,n_aes,11,1
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,2,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.02898550724637681,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,3,n_aes,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,1,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,1,n_aes,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,1,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,11,2
EXCORIATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,2,n_aes,11,2
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,0,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,0,n_aes,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,1,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,1,n_aes,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,0,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0,n_pct,11,3
FACIAL BONES FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,0,n_aes,11,3
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,1,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.0144927536231884,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,2,n_aes,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,1,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,1,n_aes,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,2,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,11,4
FALL,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,2,n_aes,11,4
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,1,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.0144927536231884,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,2,n_aes,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,2,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,2,n_aes,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,0,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0,n_pct,11,5
HIP FRACTURE,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,0,n_aes,11,5
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,0,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,0,n_aes,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,0,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,0,n_aes,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,1,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,11,7
JOINT DISLOCATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,1,n_aes,11,7
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,1,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0.0144927536231884,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,1,n_aes,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,0,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,0,n_aes,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,2,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,11,8
SKIN LACERATION,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,2,n_aes,11,8
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_n,0,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,distinct_pct,0,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Placebo,n,0,n_aes,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_n,0,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,distinct_pct,0,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline High Dose,n,0,n_aes,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_n,1,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,11,9
WOUND,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",Xanomeline Low Dose,n,2,n_aes,11,9
INVESTIGATIONS,INVESTIGATIONS,Placebo,distinct_n,10,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Placebo,distinct_pct,0.14492753623188406,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Placebo,n,19,n_aes,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline High Dose,distinct_n,5,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline High Dose,n,6,n_aes,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,8,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.09302325581395347,n_pct,12,15
INVESTIGATIONS,INVESTIGATIONS,Xanomeline Low Dose,n,15,n_aes,12,15
BIOPSY,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,1
BIOPSY,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,1
BIOPSY,INVESTIGATIONS,Placebo,n,0,n_aes,12,1
BIOPSY,INVESTIGATIONS,Xanomeline High Dose,distinct_n,1,n_pct,12,1
BIOPSY,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,12,1
BIOPSY,INVESTIGATIONS,Xanomeline High Dose,n,1,n_aes,12,1
BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,1
BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,1
BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,1
BIOPSY PROSTATE,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Placebo,n,0,n_aes,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline High Dose,distinct_n,1,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline High Dose,n,1,n_aes,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,2
BIOPSY PROSTATE,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,2
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Placebo,n,1,n_aes,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,3
BLOOD ALKALINE PHOSPHATASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,3
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,1,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,1,n_aes,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,4
BLOOD CHOLESTEROL INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,4
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Placebo,n,2,n_aes,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,5
BLOOD CREATINE PHOSPHOKINASE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,5
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,1,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,2,n_aes,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,6
BLOOD GLUCOSE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,1,n_aes,12,6
BLOOD URINE PRESENT,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Placebo,n,1,n_aes,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,7
BLOOD URINE PRESENT,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,7
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,8
BODY TEMPERATURE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,1,n_aes,12,8
CYSTOSCOPY,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Placebo,n,1,n_aes,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,9
CYSTOSCOPY,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,9
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Placebo,distinct_n,4,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Placebo,distinct_pct,0.05797101449275362,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Placebo,n,4,n_aes,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,10
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION,INVESTIGATIONS,Xanomeline Low Dose,n,2,n_aes,12,10
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Placebo,n,1,n_aes,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,11
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED,INVESTIGATIONS,Xanomeline Low Dose,n,1,n_aes,12,11
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Placebo,distinct_n,2,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Placebo,distinct_pct,0.02898550724637681,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Placebo,n,3,n_aes,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline High Dose,distinct_n,1,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline High Dose,n,1,n_aes,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,12
ELECTROCARDIOGRAM T WAVE INVERSION,INVESTIGATIONS,Xanomeline Low Dose,n,1,n_aes,12,12
HEART RATE INCREASED,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Placebo,n,2,n_aes,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,13
HEART RATE INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,13
HEART RATE IRREGULAR,INVESTIGATIONS,Placebo,distinct_n,1,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Placebo,distinct_pct,0.0144927536231884,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Placebo,n,4,n_aes,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,0,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0,n_pct,12,14
HEART RATE IRREGULAR,INVESTIGATIONS,Xanomeline Low Dose,n,0,n_aes,12,14
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Placebo,n,0,n_aes,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,16
NASAL MUCOSA BIOPSY,INVESTIGATIONS,Xanomeline Low Dose,n,1,n_aes,12,16
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,17
NEUTROPHIL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,2,n_aes,12,17
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Placebo,n,0,n_aes,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,18
URINE ANALYSIS ABNORMAL,INVESTIGATIONS,Xanomeline Low Dose,n,2,n_aes,12,18
WEIGHT DECREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,19
WEIGHT DECREASED,INVESTIGATIONS,Xanomeline Low Dose,n,2,n_aes,12,19
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Placebo,distinct_n,0,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Placebo,distinct_pct,0,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Placebo,n,0,n_aes,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_n,0,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,distinct_pct,0,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline High Dose,n,0,n_aes,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_n,1,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,12,20
WHITE BLOOD CELL COUNT INCREASED,INVESTIGATIONS,Xanomeline Low Dose,n,2,n_aes,12,20
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,6,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.08695652173913043,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Placebo,n,8,n_aes,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,3,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,5,n_aes,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,13,8
METABOLISM AND NUTRITION DISORDERS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,1,n_aes,13,8
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,n,2,n_aes,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,2,n_aes,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,1
DECREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,1
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Placebo,n,1,n_aes,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,0,n_aes,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,2
DEHYDRATION,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,2
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Placebo,n,1,n_aes,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,0,n_aes,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,3
DIABETES MELLITUS,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,3
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Placebo,n,1,n_aes,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,0,n_aes,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,13,4
FOOD CRAVING,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,1,n_aes,13,4
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,0,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,n,0,n_aes,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,1,n_aes,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,5
HYPERCHOLESTEROLAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,5
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Placebo,n,1,n_aes,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,0,n_aes,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,6
HYPONATRAEMIA,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,6
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_n,1,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Placebo,n,2,n_aes,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline High Dose,n,2,n_aes,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,13,7
INCREASED APPETITE,METABOLISM AND NUTRITION DISORDERS,Xanomeline Low Dose,n,0,n_aes,13,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,5,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.07246376811594203,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,8,n_aes,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,8,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.11428571428571428,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,11,n_aes,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,7,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.08139534883720931,n_pct,14,7
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,10,n_aes,14,7
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,1,n_aes,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,14,1
ARTHRALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,4,n_aes,14,1
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,2,n_aes,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,14,2
ARTHRITIS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,14,2
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,2,n_aes,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,3,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,4,n_aes,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,14,3
BACK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,1,n_aes,14,3
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,0,n_aes,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,2,n_aes,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,14,4
FLANK PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,14,4
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,0,n_aes,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,2,n_aes,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,14,5
MUSCLE SPASMS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,1,n_aes,14,5
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,0,n_aes,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,14,6
MUSCULAR WEAKNESS,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,14,6
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,0,n_aes,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,14,8
MYALGIA,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,14,8
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,1,n_aes,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,14,9
PAIN IN EXTREMITY,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,14,9
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Placebo,n,2,n_aes,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,14,10
SHOULDER PAIN,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,14,10
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_n,0,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_pct,0,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,n,0,n_aes,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_n,1,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,n,1,n_aes,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_n,2,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,15,3
"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)","NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,n,3,n_aes,15,3
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_n,0,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_pct,0,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,n,0,n_aes,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_n,0,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_pct,0,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,n,0,n_aes,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_n,1,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,15,1
COLON CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,n,1,n_aes,15,1
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_n,0,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_pct,0,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,n,0,n_aes,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_n,0,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_pct,0,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,n,0,n_aes,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_n,1,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,15,2
MALIGNANT FIBROUS HISTIOCYTOMA,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,n,2,n_aes,15,2
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_n,0,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,distinct_pct,0,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Placebo,n,0,n_aes,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_n,1,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline High Dose,n,1,n_aes,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_n,0,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,distinct_pct,0,n_pct,15,4
PROSTATE CANCER,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",Xanomeline Low Dose,n,0,n_aes,15,4
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,12,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.17391304347826086,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Placebo,n,16,n_aes,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,25,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.35714285714285715,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,43,n_aes,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,22,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.2558139534883721,n_pct,16,12
NERVOUS SYSTEM DISORDERS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,42,n_aes,16,12
AMNESIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,2,n_aes,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,1
AMNESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,1
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,2
BALANCE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,3,n_aes,16,2
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,2,n_aes,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,3
BURNING SENSATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,3
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,4
COGNITIVE DISORDER,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,4
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,5
COMPLEX PARTIAL SEIZURES,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,5
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,6
COORDINATION ABNORMAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,6
DIZZINESS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,2,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Placebo,n,3,n_aes,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,11,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.15714285714285714,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,17,n_aes,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,9,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.10465116279069768,n_pct,16,7
DIZZINESS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,14,n_aes,16,7
HEADACHE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,7,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.10144927536231883,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Placebo,n,8,n_aes,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,6,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.08571428571428572,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,9,n_aes,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,16,8
HEADACHE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,4,n_aes,16,8
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,9
HEMIANOPIA HOMONYMOUS,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,9
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,10
HYPERSOMNIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,10
LETHARGY,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,11
LETHARGY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,11
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,13
PARAESTHESIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,13
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,14
PARAESTHESIA ORAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,14
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,1,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Placebo,n,1,n_aes,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,15
PARKINSON'S DISEASE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,15
PAROSMIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,2,n_aes,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,16
PAROSMIA,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,16
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,17
PARTIAL SEIZURES WITH SECONDARY GENERALISATION,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,17
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,1,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Placebo,n,1,n_aes,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,18
PSYCHOMOTOR HYPERACTIVITY,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,18
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,2,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Placebo,n,3,n_aes,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,16,19
SOMNOLENCE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,5,n_aes,16,19
STUPOR,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,0,n_aes,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,16,20
STUPOR,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,1,n_aes,16,20
SYNCOPE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,3,n_aes,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,5,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.05813953488372093,n_pct,16,21
SYNCOPE,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,7,n_aes,16,21
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,16,22
SYNCOPE VASOVAGAL,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,0,n_aes,16,22
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Placebo,distinct_n,0,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Placebo,distinct_pct,0,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Placebo,n,0,n_aes,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline High Dose,n,1,n_aes,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,16,23
TRANSIENT ISCHAEMIC ATTACK,NERVOUS SYSTEM DISORDERS,Xanomeline Low Dose,n,3,n_aes,16,23
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Placebo,distinct_n,10,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.14492753623188406,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Placebo,n,14,n_aes,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,8,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.11428571428571428,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,11,n_aes,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,11,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.12790697674418605,n_pct,17,16
PSYCHIATRIC DISORDERS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,15,n_aes,17,16
AGITATION,PSYCHIATRIC DISORDERS,Placebo,distinct_n,2,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Placebo,n,2,n_aes,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,17,1
AGITATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,3,n_aes,17,1
ANXIETY,PSYCHIATRIC DISORDERS,Placebo,distinct_n,1,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Placebo,n,2,n_aes,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,17,2
ANXIETY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,4,n_aes,17,2
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Placebo,distinct_n,1,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Placebo,n,1,n_aes,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,3
COMPLETED SUICIDE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,3
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Placebo,distinct_n,2,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Placebo,n,2,n_aes,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,3,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.03488372093023256,n_pct,17,4
CONFUSIONAL STATE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,3,n_aes,17,4
DELIRIUM,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,5
DELIRIUM,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,5
DELUSION,PSYCHIATRIC DISORDERS,Placebo,distinct_n,1,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Placebo,n,1,n_aes,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,6
DELUSION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,6
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,17,7
DEPRESSED MOOD,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,2,n_aes,17,7
DISORIENTATION,PSYCHIATRIC DISORDERS,Placebo,distinct_n,1,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Placebo,n,1,n_aes,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,8
DISORIENTATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,8
HALLUCINATION,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,9
HALLUCINATION,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,9
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,10
"HALLUCINATION, VISUAL",PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,10
INSOMNIA,PSYCHIATRIC DISORDERS,Placebo,distinct_n,2,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Placebo,n,3,n_aes,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,2,n_aes,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,11
INSOMNIA,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,11
IRRITABILITY,PSYCHIATRIC DISORDERS,Placebo,distinct_n,1,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Placebo,n,2,n_aes,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,17,12
IRRITABILITY,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,1,n_aes,17,12
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,13
LIBIDO DECREASED,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,13
LISTLESS,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,14
LISTLESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,14
NIGHTMARE,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,1,n_aes,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,17,15
NIGHTMARE,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,0,n_aes,17,15
RESTLESSNESS,PSYCHIATRIC DISORDERS,Placebo,distinct_n,0,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Placebo,distinct_pct,0,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Placebo,n,0,n_aes,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline High Dose,n,0,n_aes,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,17,17
RESTLESSNESS,PSYCHIATRIC DISORDERS,Xanomeline Low Dose,n,2,n_aes,17,17
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Placebo,distinct_n,4,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0.05797101449275362,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Placebo,n,5,n_aes,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,3,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,4,n_aes,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,4,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0.04651162790697674,n_pct,18,8
RENAL AND URINARY DISORDERS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,4,n_aes,18,8
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Placebo,distinct_n,0,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Placebo,n,0,n_aes,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,1,n_aes,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,18,1
CALCULUS URETHRAL,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,0,n_aes,18,1
DYSURIA,RENAL AND URINARY DISORDERS,Placebo,distinct_n,1,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Placebo,n,1,n_aes,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,0,n_aes,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,18,2
DYSURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,1,n_aes,18,2
ENURESIS,RENAL AND URINARY DISORDERS,Placebo,distinct_n,0,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Placebo,n,0,n_aes,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,0,n_aes,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,18,3
ENURESIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,1,n_aes,18,3
INCONTINENCE,RENAL AND URINARY DISORDERS,Placebo,distinct_n,0,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Placebo,n,0,n_aes,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,0,n_aes,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,18,4
INCONTINENCE,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,1,n_aes,18,4
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Placebo,distinct_n,1,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Placebo,n,1,n_aes,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,2,n_aes,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,18,5
MICTURITION URGENCY,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,1,n_aes,18,5
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Placebo,distinct_n,1,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Placebo,n,1,n_aes,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,1,n_aes,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,18,6
NEPHROLITHIASIS,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,0,n_aes,18,6
POLLAKIURIA,RENAL AND URINARY DISORDERS,Placebo,distinct_n,1,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Placebo,n,2,n_aes,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline High Dose,n,0,n_aes,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,18,7
POLLAKIURIA,RENAL AND URINARY DISORDERS,Xanomeline Low Dose,n,0,n_aes,18,7
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_n,2,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,n,4,n_aes,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,n,1,n_aes,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,19,3
REPRODUCTIVE SYSTEM AND BREAST DISORDERS,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,n,0,n_aes,19,3
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_n,1,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,n,2,n_aes,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,n,1,n_aes,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,19,1
BENIGN PROSTATIC HYPERPLASIA,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,n,0,n_aes,19,1
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_n,1,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Placebo,n,2,n_aes,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline High Dose,n,0,n_aes,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,19,2
PELVIC PAIN,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,Xanomeline Low Dose,n,0,n_aes,19,2
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,10,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.14492753623188406,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,15,n_aes,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,10,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.14285714285714285,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,22,n_aes,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,10,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.11627906976744186,n_pct,20,15
"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,16,n_aes,20,15
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,1,n_aes,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,1
ALLERGIC GRANULOMATOUS ANGIITIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,1
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,3,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.04347826086956521,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,4,n_aes,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,5,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,7,n_aes,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,6,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.06976744186046512,n_pct,20,2
COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,9,n_aes,20,2
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,0,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,0,n_aes,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,3
DYSPHONIA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,1,n_aes,20,3
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,1,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.0144927536231884,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,1,n_aes,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,1,n_aes,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,4
DYSPNOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,1,n_aes,20,4
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,1,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.0144927536231884,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,1,n_aes,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,0,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,0,n_aes,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,5
EMPHYSEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,5
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,2,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,2,n_aes,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,6
EPISTAXIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,1,n_aes,20,6
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,1,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.0144927536231884,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,2,n_aes,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,0,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,0,n_aes,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,7
HAEMOPTYSIS,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,7
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,3,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.04347826086956521,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,3,n_aes,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,3,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.04285714285714286,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,4,n_aes,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,8
NASAL CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,1,n_aes,20,8
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,2,n_aes,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,9
PHARYNGEAL ERYTHEMA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,9
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,1,n_aes,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,10
PHARYNGOLARYNGEAL PAIN,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,1,n_aes,20,10
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,1,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.0144927536231884,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,2,n_aes,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,0,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,0,n_aes,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,11
POSTNASAL DRIP,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,11
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,1,n_aes,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,12
PRODUCTIVE COUGH,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,12
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,1,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0.0144927536231884,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,2,n_aes,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,0,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,0,n_aes,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,13
RALES,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,13
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,1,n_aes,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,0,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0,n_pct,20,14
RESPIRATORY TRACT CONGESTION,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,0,n_aes,20,14
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_n,0,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,distinct_pct,0,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Placebo,n,0,n_aes,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_n,1,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline High Dose,n,2,n_aes,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_n,1,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,20,16
RHINORRHOEA,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",Xanomeline Low Dose,n,2,n_aes,20,16
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,21,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.30434782608695654,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,47,n_aes,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,42,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.6,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,111,n_aes,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,42,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.4883720930232558,n_pct,21,17
SKIN AND SUBCUTANEOUS TISSUE DISORDERS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,118,n_aes,21,17
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,1
ACTINIC KERATOSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,1
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,1,n_aes,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,2
ALOPECIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,2
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,2,n_aes,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,5,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.05813953488372093,n_pct,21,3
BLISTER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,8,n_aes,21,3
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,3,n_aes,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,4
COLD SWEAT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,4
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,1,n_aes,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,5
DERMATITIS ATOPIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,5
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,21,6
DERMATITIS CONTACT,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,21,6
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,1,n_aes,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,7
DRUG ERUPTION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,7
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,9,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.13043478260869565,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,13,n_aes,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,14,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.2,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,22,n_aes,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,15,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.1744186046511628,n_pct,21,8
ERYTHEMA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,24,n_aes,21,8
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,2,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,2,n_aes,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,8,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.11428571428571428,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,10,n_aes,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,4,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.04651162790697674,n_pct,21,9
HYPERHIDROSIS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,5,n_aes,21,9
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,8,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.11594202898550723,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,11,n_aes,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,26,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.37142857142857144,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,38,n_aes,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,23,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.26744186046511625,n_pct,21,10
PRURITUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,35,n_aes,21,10
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,21,11
PRURITUS GENERALISED,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,4,n_aes,21,11
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,5,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.07246376811594203,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,9,n_aes,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,11,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.15714285714285714,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,18,n_aes,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,13,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.1511627906976744,n_pct,21,12
RASH,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,18,n_aes,21,12
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,21,13
RASH ERYTHEMATOUS,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,21,13
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,3,n_aes,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,14
RASH MACULO-PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,14
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,2,n_aes,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,15
RASH PAPULAR,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,15
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,2,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,3,n_aes,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,21,16
RASH PRURITIC,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,21,16
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,21,18
SKIN EXFOLIATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,2,n_aes,21,18
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,3,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.04347826086956521,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,4,n_aes,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,5,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.07142857142857142,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,8,n_aes,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,6,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.06976744186046512,n_pct,21,19
SKIN IRRITATION,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,13,n_aes,21,19
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,1,n_aes,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,20
SKIN ODOUR ABNORMAL,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,20
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,1,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,2,n_aes,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,0,n_aes,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,21,21
SKIN ULCER,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,0,n_aes,21,21
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_n,0,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,distinct_pct,0,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Placebo,n,0,n_aes,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline High Dose,n,2,n_aes,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,21,22
URTICARIA,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,Xanomeline Low Dose,n,3,n_aes,21,22
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Placebo,distinct_n,0,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Placebo,distinct_pct,0,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Placebo,n,0,n_aes,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,distinct_n,1,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,n,1,n_aes,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,distinct_n,0,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,distinct_pct,0,n_pct,22,2
SOCIAL CIRCUMSTANCES,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,n,0,n_aes,22,2
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Placebo,distinct_n,0,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Placebo,distinct_pct,0,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Placebo,n,0,n_aes,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,distinct_n,1,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline High Dose,n,1,n_aes,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,distinct_n,0,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,distinct_pct,0,n_pct,22,1
ALCOHOL USE,SOCIAL CIRCUMSTANCES,Xanomeline Low Dose,n,0,n_aes,22,1
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_n,2,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_pct,0.02898550724637681,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Placebo,n,2,n_aes,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_n,2,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_pct,0.02857142857142857,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,n,2,n_aes,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_n,1,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,23,5
SURGICAL AND MEDICAL PROCEDURES,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,n,1,n_aes,23,5
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_n,0,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_pct,0,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,n,0,n_aes,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_n,1,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,n,1,n_aes,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_n,0,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_pct,0,n_pct,23,1
ACROCHORDON EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,n,0,n_aes,23,1
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_n,1,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_pct,0.0144927536231884,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Placebo,n,1,n_aes,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_n,0,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_pct,0,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,n,0,n_aes,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_n,1,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,23,2
CATARACT OPERATION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,n,1,n_aes,23,2
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_n,1,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_pct,0.0144927536231884,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Placebo,n,1,n_aes,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_n,0,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_pct,0,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,n,0,n_aes,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_n,0,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_pct,0,n_pct,23,3
EYE LASER SURGERY,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,n,0,n_aes,23,3
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_n,0,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,distinct_pct,0,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Placebo,n,0,n_aes,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_n,1,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline High Dose,n,1,n_aes,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_n,0,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,distinct_pct,0,n_pct,23,4
SKIN LESION EXCISION,SURGICAL AND MEDICAL PROCEDURES,Xanomeline Low Dose,n,0,n_aes,23,4
VASCULAR DISORDERS,VASCULAR DISORDERS,Placebo,distinct_n,3,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Placebo,distinct_pct,0.04347826086956521,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Placebo,n,7,n_aes,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline High Dose,n,1,n_aes,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,4,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0.04651162790697674,n_pct,24,5
VASCULAR DISORDERS,VASCULAR DISORDERS,Xanomeline Low Dose,n,5,n_aes,24,5
HOT FLUSH,VASCULAR DISORDERS,Placebo,distinct_n,0,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Placebo,distinct_pct,0,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Placebo,n,0,n_aes,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline High Dose,n,0,n_aes,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,24,1
HOT FLUSH,VASCULAR DISORDERS,Xanomeline Low Dose,n,1,n_aes,24,1
HYPERTENSION,VASCULAR DISORDERS,Placebo,distinct_n,1,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Placebo,n,2,n_aes,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline High Dose,n,0,n_aes,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,2,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0.02325581395348837,n_pct,24,2
HYPERTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,n,3,n_aes,24,2
HYPOTENSION,VASCULAR DISORDERS,Placebo,distinct_n,2,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Placebo,distinct_pct,0.02898550724637681,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Placebo,n,3,n_aes,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,n,0,n_aes,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,1,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0.01162790697674418,n_pct,24,3
HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,n,1,n_aes,24,3
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Placebo,distinct_n,1,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Placebo,distinct_pct,0.0144927536231884,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Placebo,n,2,n_aes,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,0,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline High Dose,n,0,n_aes,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,24,4
ORTHOSTATIC HYPOTENSION,VASCULAR DISORDERS,Xanomeline Low Dose,n,0,n_aes,24,4
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Placebo,distinct_n,0,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Placebo,distinct_pct,0,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Placebo,n,0,n_aes,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline High Dose,distinct_n,1,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline High Dose,distinct_pct,0.01428571428571428,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline High Dose,n,1,n_aes,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_n,0,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline Low Dose,distinct_pct,0,n_pct,24,6
WOUND HAEMORRHAGE,VASCULAR DISORDERS,Xanomeline Low Dose,n,0,n_aes,24,6
